Analyst Reports
The analyst research linked below is commissioned and paid for by ExpreS2ion Biotech Holding AB to support market understanding of the company. Reports are currently produced by Redeye and H.C. Andersen Capital, and were previously produced by Analysguiden (Aktiespararna) and Pareto Securities, under agreements with ExpreS2ion. These reports are prepared independently by the respective research providers, who retain full editorial control over their analyses and conclusions.
ExpreS2ion may review factual information for accuracy before publication but does not influence the analysts’ views, assumptions, or investment conclusions. Because the research is commissioned, investors should be aware of the potential for conflicts of interest.
The reports are provided for informational purposes only and do not constitute investment advice, recommendations, or an offer to buy or sell financial instruments. Investors should always base investment decisions on ExpreS2ion’s official disclosures, regulatory filings, and their own assessment.
| Date | Report | Author |
|---|---|---|
| May 5 |
Rights Issue Outcome |
![]() |
| April 22 |
Encouraging data from phase Ia BIO-002 study |
![]() |
| April 10 |
New patent application in Hong Kong |
![]() |
| April 7 |
Final terms set on SEK53m Rights Issue |
|
| April 7 |
Finalized terms of SEK53m Rights Issue |
![]() |
| March 25 |
ES2B-C001 clears another hurdle |
|
| March 25 |
Positive Interim Data Advancing to Higher Dose |
![]() |
| March 2 |
Incremental Phase I data strengthen early biological validation of ES2B-C001 |
|
| March 2 |
Rights issue of SEK53m |
![]() |
| February 24 |
Progress continues for both pipeline and partner-driven programs |
|
| February 19 |
Q4 2025 - Progress on Multiple Fronts |
![]() |
| February 9 |
Redeye Initiates Coverage (watch video) |
![]() |
| February 3 |
Updated Phase I Immunogenicity Data |
![]() |
| February 3 |
A Polyclonal Plot Twist |
![]() |
| January 14 |
Early Phase I clinical validation of ES2B-C001 de-risks near term development |
| Date | Report | Author |
|---|---|---|
| December 23 |
Market value below cash balance |
|
| December 9 |
Start för fas 1 inom kort (SE) |
![]() |
| December 9 |
Austrian milestone (EN) |
![]() |
| November 14 |
Q3 2024 financial results (EN) |
![]() |
| November 1 |
Reverse Split (EN) |
![]() |
| October 21 |
Early stage biotech company with a phase 3 validated platform |
|
| October 17 |
Enters term sheet on commercialization of malaria vaccines |
|
| October 15 |
SIIPL Term Sheet (EN) |
![]() |
| September 22 |
Opsummering fra fysisk investorseminar |
|
| August 22 |
At the gates of Phase I (EN) |
![]() |
| August 22 |
Vid porten till fas 1 (SE) |
![]() |
| August 15 |
2024 Second Quarter Results (EN) |
![]() |
| July 11 |
2024 Rights Issue results (EN) |
![]() |
| May 23 |
Improving cash position (EN) |
![]() |
| May 23 |
Förbättrat kassa inför fas1 (SE) |
![]() |
| May 16 |
024 First Quarter Results (EN) |
![]() |
| May 3 |
2024 Rights Issue (EN) |
![]() |
| April 23 |
AdaptVac Dividend (EN) |
![]() |
| April 16 |
Completion of pre-clinical safety (EN) |
![]() |
| February 22 |
ABNCoV2 milestone payment (EN) |
![]() |
| February 15 |
Breast cancer on stage (EN) |
![]() |
| February 15 |
Bröstcancer i fokus (SE) |
![]() |
| February 8 | 2023 YE Report (Newsflash) (EN) | ![]() |
| Date | Report | Author |
|---|---|---|
| December 4 |
Pipeline addition - Nipah |
![]() |
| December 4 |
Spotlight: Cancer vaccine ES2B-C001 |
![]() |
| November 27 |
New strategy evolving (EN) |
![]() |
| November 27 |
Ny strategi tar form (SE) |
![]() |
| August 17 |
Evaluating BC strategic options (Newsflash) (EN) |
![]() |
| June 27 |
ABNCoV2 phase II meets primary endpoint (Newsflash) (EN) |
![]() |
| June 16 |
ABNCoV2 strong durability data (Newsflash) (EN) |
![]() |
| May 16 |
2023 Q1 Report (Newsflash) (EN) |
![]() |
| April 18 |
Initial gross proceeds of SEK 54.5m (EN) |
![]() |
| March 15 |
Ever-changing landscape (EN) |
![]() |
| March 15 |
Ett föränderligt landskap (SE) |
![]() |
| March 6 |
2023 Right Issue Announcement (EN) |
![]() |
| March 3 |
Mucosal Vaccine (EN) |
![]() |
| February 9 |
2022 YE Report Newsflash (EN) |
![]() |
| Date | Report | Author |
|---|---|---|
| December 6 |
Evaxion CMV vaccine collaboration Newsflash (EN) |
![]() |
| November 18 |
Promising long-term data (EN) |
![]() |
| November 18 |
Lovande långtidsdata (SE) |
![]() |
| November 17 |
9M 2022 Report Newsflash (EN) |
![]() |
| October 24 |
ES2B-C001 positive preclinical data published (EN) |
![]() |
| October 18 |
ABNCoV2 reports positive phase II durability data (EN) |
![]() |
| September 22 |
COVID vaccine phase III trial ongoing (EN) |
![]() |
| April 8 |
Cash position to be further increased (EN) |
![]() |
| March 8 |
A moving target (EN) |
![]() |
| March 8 |
Ett rörligt mål (SE) |
![]() |
| March 1 |
Further progress with COVID-19 vaccine (EN) |
![]() |
| January 10 |
Exciting topline preclinical results for ES2B-C001 (EN) |
![]() |
| Date | Report | Author |
|---|---|---|
| December 9 |
Solid data open for final phase (EN) |
![]() |
| December 9 |
Resultat öppnar vägen för slutfas (SE) |
![]() |
| December 7 |
Great ABNCoV2 Phase II top line results (EN) |
![]() |
| November 19 |
Phase 2 data pending (EN) |
![]() |
| November 19 |
Fas 2-resultat inom kort (SE) |
![]() |
| November 17 |
COVID-19 vaccine Phase II readout on the horizon (EN) |
![]() |
| August 23 |
Funding still pending (EN) |
![]() |
| August 23 |
I väntan på finansiering (SE) |
![]() |
| August 20 |
Initiation of Phase II trial just around the corner (EN) |
![]() |
| August 9 |
Great COUGH-1 headline results (EN) |
![]() |
| June 24 |
Rights to COVID-19 Challenge (Initiation) (EN) |
![]() |
| April 22 |
First human data reassuring (EN) |
![]() |
| April 22 |
Första data på människa (SE) |
![]() |
| January 27 |
Getting Close To Patients (EN) |
![]() |
| January 27 |
Test På Människa Inom Kort (SE) |
![]() |
| Date | Report | Author |
|---|---|---|
| September 3 |
Broadening the Portfolio (EN) |
![]() |
| September 3 |
Minskad risk med breddad portfölj (SE) |
![]() |
| June 8 |
I den stora kapplöpningen (SE) |
![]() |
| Date | Report | Author |
|---|---|---|
| November 21 |
Potential at Reduced Risk (EN) |
![]() |
| November 21 |
Potential till Reducerad Risk (SE) |
![]() |
English reports
Analysguiden
22 August 2024 | Analysguiden - At the gates of Phase I
23 May 2024 | Analysguiden - Improving cash position
15 February 2024 | Analysguiden - Breast cancer on stage
27 Nov 2023 | Analysguiden - New strategy evolving
15 Mar 2023 | Analysguiden - Ever-changing landscape
18 Nov 2022 | Analysguiden - Promising long-term data
13 Jun 2022 | Analyseguiden - Preparing for the final
8 Mar 2022 | Analysguiden - A moving target
9 Dec 2021 | Analysguiden - Solid data open for final phase
19 Nov 2021 | Analysguiden - Phase 2 data pending
23 Aug 2021 | Analysguiden - Funding still pending
22 Apr 2021 | Analysguiden - First human data reassuring
27 Jan 2021 | Analysguiden - Getting Close To Patients
3 Sep 2020 | Analysguiden - Broadening the Portfolio
21 Nov 2019 | Analysguiden - Potential at Reduced Risk
Pareto Securities
17 October 2024 Pareto | SIIPL Term Sheet
15 August 2024 Pareto | 2024 Second Quarter Results
11 July 2024 Pareto | 2024 Rights Issue results
16 May 2024 Pareto | 2024 First Quarter Results
3 May 2024 Pareto | 2024 Rights Issue
23 April 2024 Pareto | AdaptVac Dividend
16 April 2024 Pareto | Completion of pre-clinical safety
22 February 2024 Pareto | ABNCoV2 milestone payment
8 February 2024 Pareto | 2023 YE Report (Newsflash)
4 December 2023 Pareto | Pipeline addition - Nipah
4 December 2023 Pareto | Spotlight: Cancer vaccine ES2B-C001
17 August 2023 | Pareto - Evaluating BC strategic options (Newsflash)
27 June 2023 Pareto | ABNCoV2 phase II meets primary endpoint (Newsflash)
16 June 2023 Pareto | ABNCoV2 strong durability data (Newsflash)
16 May 2023 Pareto | 2023 Q1 Report (Newsflash)
18 April 2023 Pareto | Initial gross proceeds of SEK 54.5m
6 March 2023 Pareto | 2023 Right Issue Announcement
3 March 2023 Pareto | Mucosal Vaccine
9 February 2023 Pareto | 2022 YE Report Newsflash
6 December 2022 Pareto | Evaxion CMV vaccine collaboration Newsflash
17 November 2022 Pareto | 9M 2022 Report Newsflash
24 Oct 2022 Pareto | ES2B-C001 positive preclinical data published
18 Oct 2022 Pareto | ABNCoV2 reports positive phase II durability data
22 Sep 2022 Pareto | COVID vaccine phase III trial ongoing
8 Apr 2022 Pareto | Cash position to be further increased
1 Mar 2022 Pareto | Further progress with COVID-19 vaccine
10 Jan 2022 Pareto | Exciting topline preclinical results for ES2B-C001
7 Dec 2021 | Pareto - Great ABNCoV2 Phase II top line results
17 Nov 2021 | Pareto - COVID-19 vaccine Phase II readout on the horizon
20 Aug 2021 | Pareto - Initiation of Phase II trial just around the corner
9 Aug 2021 | Pareto - Great COUGH-1 headline results
24 Jun 2021 | Pareto - Rights to COVID-19 Challenge (Initiation)
Swedish reports
Analysguiden
22 August 2024 | Analysguiden - Vid porten till fas 1
23 May 2024 | Analysguiden - Förbättrat kassa inför fas1
15 February 2024 | Analysguiden - Bröstcancer i fokus
27 Nov 2023 | Analysguiden - Ny strategi tar form
15 Mar 2023 | Analysguiden - Ett föränderligt landskap
18 Nov 2022 | Analysguiden - Lovande långtidsdata
13 Jun 2022 | Analysguiden - Bavarian nära fas 3-start
8 Mar 2022 | Analysguiden - Ett rörligt mål
9 Dec 2021 | Analysguiden - Resultat öppnar vägen för slutfas
19 Nov 2021 | Analysguiden - Fas 2-resultat inom kort
23 Aug 2021 | Analysguiden - I väntan på finansiering
22 Apr 2021 | Analysguiden - Första data på människa
27 Jan 2021 | Analysguiden -Test På Människa Inom Kort
3 Sep 2020 | Analysguiden - Minskad risk med breddad portfölj



